Compare Duolingo Inc (DUOL) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Kymera Therapeutics Inc. Common Stock — how do they compare? Duolingo Inc trades at $138.28 (market cap $6.55B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 138 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| DUOL | KYMR | |
|---|---|---|
Market Cap | $6.55B | $8.87B |
Volume | 767,658 | 779,107 |
Sector | Technology | Health |
52-Week High | $341.08 | $127.31 |
52-Week Low | $90.03 | $55.80 |
Typical Hold Time | 138 Days | 0 Days |
Enterprise Value | $5.33B | $8.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $139.73, down 5.42% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental performance with 2025 revenue reaching $1.04 billion and net income of $414 million, representing a robust 39.9% profit margin. Recent earnings beats and analyst consensus of $142.50 price target suggest underlying strength despite recent price weakness. Technical indicators show a bullish moving average signal with neutral oscillators, while institutional sentiment remains mixed with notable insider selling activity.
Duolingo presents a compelling growth story with exceptional profitability metrics and consistent earnings outperformance. The primary investment opportunity lies in the company's AI-driven platform expansion and strong user growth momentum. Key risks include CEO share liquidations, competitive pressures in edtech, and valuation concerns at current levels. The stock's current discount to consensus target offers potential upside if execution continues.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
